AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
AltaRex Corp has signed a Memorandum of Understanding establishing a joint collaboration with Epigen Inc for the purposes of the research and development of antibody based treatments for a potential twelve cancers associated with the human carcinoma antigen (HCA).
HCA is Epigen's proprietary cancer specific antigen that appears in circulation in early stage disease and is associated with the vast majority of epithelial cancers including prostate, ovarian, breast and non-small cell lung cancers.
The companies expect to enter into a definitive agreement within 60 days.
Epigen brings to the collaboration the antigen HCA and a series of foreign …